Trial Details 90 Total Sites

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

phase

Phase 3

status

Recruiting

enrollment

870

score

58

start date

2019-06-13

last updated

2022-01-12

biomarkers

N/A

New York City, New York
facility
New York University Perlmutter Cancer Center ( Site 0008)
1 facility
Recruiting
Houston, Texas
facility
MD Anderson Cancer Center ( Site 0063)
1 facility
Recruiting
Indianapolis, Indiana
facility
Indiana University Melvin and Bren Simon Cancer Center ( Site 0004)
1 facility
Recruiting
Seattle, Washington
facility
Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0033)
1 facility
Recruiting
Portland, Oregon
facility
Portland VA Medical Center ( Site 0084)
1 facility
Recruiting
Washington, Washington, D.C.
facility
Georgetown University Medical Center ( Site 0022)
1 facility
Recruiting
Tulsa, Oklahoma
facility
Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021)
1 facility
Recruiting
New Orleans, Louisiana
facility
Ochsner Medical Center ( Site 0049)
1 facility
Recruiting
Cleveland, Ohio
facility
University Hospitals Cleveland Medical Center ( Site 0038)
1 facility
Recruiting
St. Louis, Missouri
facility
Mercy Hospital Saint Louis ( Site 0064)
1 facility
Recruiting
Pittsburgh, Pennsylvania
facility
Allegheny General Hospital ( Site 0048)
1 facility
Recruiting
Orlando, Florida
facility
AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0005)
1 facility
Recruiting